Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
Authors:
- Christopher R. CabanskiCCChristopher R. Cabanski
- Alexandra DrakakiADAlexandra Drakaki
- Danny N. KhalilDKDanny N. Khalil
- Bilal A. SiddiquiBilal A. Siddiqui
- Sreyashi BasuSBSreyashi Basu
- Diane M. Da SilvaDSDiane M. Da Silva
- Shikha GautamSGShikha Gautam
- Farah A. AlayliFAFarah A. Alayli
- Justin FairchildJFJustin Fairchild
- 16 October 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (42)
Abstract
Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated the efficacy, safety, and biomarkers of escalating ipilimumab doses combined with nivolumab. Patients received ipilimumab 1 milligram per kilogram (mg/kg) + nivolumab 360 mg (I1+N360), ipilimumab 3 mg/kg + nivolumab 1 mg/kg (I3+N1), or ipilimumab 5 mg/kg + nivolumab 1 mg/kg (I5+N1). Coprimary endpoints were 6-month disease control rate (DCR) and changes in tumoral CD8 percentage. Thirty-two patients were enrolled. DCRs were 33% (4 of 12) for I1+N360, 20% (1 of 5) for I3+N1, and 20% (3 of 15) for I5+N1. Across cohorts, tumoral CD8 percentage increased by a median of 5.0%. Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets.Keywords
Funding Information
- Cancer Research Institute (CR15545)
- Prostate Cancer Foundation (Young Investigator Award)
- Bristol-Myers Squibb
- American Society of Clinical Oncology (Cancer Foundation Career Development Award)
- Parker Institute for Cancer Immunotherapy
This publication has 56 references indexed in Scilit:
- Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyAnnals of Oncology, 2025
- Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialAnnals of Oncology, 2024
- Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor TherapyAdvanced Science, 2024
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Targeting TREM2 on tumor-associated macrophages enhances immunotherapyCell Reports, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesCell, 2021
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 TrialCancer Cell, 2020
- TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyCell, 2020
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015